Searchable News & Info From Reliable Online Sources.
- The borough where families are slowly disappearing
Islington is a snapshot of a trend playing out across inner London, Britain and much of the world. [TheTopNews] Read More.9 mins ago - France passes law banning under-15s from social mediaThe law will require social media platforms in France to verify all users age from January. [TheTopNews] Read More.2 hours ago
- Ford recalls nearly 388,000 vehicles over second-row seat injury hazard
Ford is recalling nearly 388,000 SUVs because an issue with the second-row easy-entry seats could increase the risk of injury, according to federal regulators.A total of 387,911 vehicles are affected, including certain 2020-2026 Ford Explorer and 2020-2027 Lincoln Aviator models, the National Highway Traffic Safety Administration (NHTSA) said in its recall notice.The NHTSA said the vehicles may have a defect that could cause a second-row seat to tip or slide unexpectedly while the vehicle is moving.FORD RECALLS MORE THAN 110,000 MUSTANG VEHICLES OVER WINDSHIELD WIPER, DRIVETRAIN DEFECTS"A seat that moves unexpectedly may not properly restrain an occupant during a crash, increasing the risk of injury," the NHTSA said."The switch for the easy-entry second-row outer seats may bind or stick, resulting in the seats unlatching, tipping, or sliding unexpectedly," the agency explained.The agency noted some warning signs that vehicle owners should keep an eye out for."If the button is stuck in the down position, the customer may not be able to use the easy entry feature or return the seat to its normal position after using the easy entry feature," the notice reads.Ford's Critical Concern Review Group identified 14 reports as of June 16, 2026, of unintended second-row seat movement while the vehicle was in drive. Six involved vehicles that had already received a remedy under an earlier recall, while eight involved vehicles that were not covered by the previous campaign. Ford said it was not aware of any crashes or injuries related to the issue.BMW RECALLS NEARLY 30K VEHICLES OVER ENGINE STARTER DEFECT THAT COULD CAUSE FIRECLICK HERE TO GET FOX BUSINESS ON THE GOOwners will be instructed to take their vehicles to a Ford or Lincoln dealership, where the second-row easy-entry switch bezel and housing will be replaced with a revised design at no charge.Owner notification letters will be mailed out later this month, with another letter about the remedy expected to be sent out in January. [TheTopNews] Read More.3 hours ago - Cracker Barrel sells Maple Street Biscuit Company, closes 16 locationsCracker Barrel is selling restaurant properties and exiting its Maple Street Biscuit Company business as it works to cut debt and improve profits.The Southern country-themed chain said Monday it sold the Maple Street brand and assets tied to 35 locations to Biscuit Belly LLC. Cracker Barrel will close the remaining 16 Maple Street restaurants.In a separate move, Cracker Barrel also completed a sale-leaseback deal involving 26 company-owned locations, generating roughly $77 million in net proceeds.The company plans to use the money to pay down debt while continuing to operate the restaurants by leasing the properties from the new owner.CRACKER BARREL RESPONDS TO REPORTS ABOUT EMPLOYEE DINING REQUIREMENTS DURING WORK TRAVEL"These efforts reflect the discipline we bring to managing our business and balance sheet as we position Cracker Barrel for long-term success and shareholder value creation," Julie Masino, president and CEO of Cracker Barrel, said in a statement. "Our sale-leaseback transaction will allow us to opportunistically reduce debt while monetizing a portion of our owned real estate at an attractive valuation."Masino added, "Divesting Maple Street sharpens our focus on the core Cracker Barrel brand and is expected to improve profitability."Biscuit Belly, which currently has 15 locations, said the deal will allow it to expand more quickly. It plans to convert the acquired Maple Street restaurants into Biscuit Belly locations over the next 18 to 24 months. CRACKER BARREL SALES, TRAFFIC CONTINUE TO SLUMP MONTHS AFTER FAILED REBRANDThe first conversions will begin in the greater Cincinnati area and Richmond, Virginia. The deal will more than triple Biscuit Belly’s footprint and is expected to help the chain grow to more than 60 locations by the end of 2028."When we looked at Maple Street's geography, footprints, and established teams, a light bulb went off," Chad Coulter, co-founder and CEO of Biscuit Belly, said in a statement.Maple Street accounted for less than 2% of Cracker Barrel’s annual revenue. Cracker Barrel said the sale is expected to improve adjusted EBITDA beginning in fiscal 2027.Cracker Barrel expects to record between $37 million and $39 million in non-cash charges tied to the Maple Street exit during its fiscal fourth quarter. It also anticipates between $6 million and $8 million in additional cash costs.CRACKER BARREL’S TURNAROUND HITS EARLY SNAGS; CEO WARNS RECOVERY WILL 'TAKE TIME' AFTER REBRAND FIASCOThe moves come as Cracker Barrel, which operates roughly 660 company-owned locations across 43 states, works to move past backlash over proposed changes to… [TheTopNews] Read More.4 hours ago
- Trump unveils phased tariffs on generic drugs to boost US productionPresident Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage pharmaceutical companies to manufacture more medicines in the U.S.In a Truth Social post, Trump said all generic drugs imported into the U.S. will continue to face a 0% tariff beginning Aug. 1, 2026, for a two-year transition period. After that, the tariff will rise to 100% for one year before increasing to 200%."Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two-year period of time, after which the TARIFF will be raised to 100% for a one-year period of time, and 200% thereafter," Trump wrote.The president said the phased approach is intended to give pharmaceutical companies time to move production to the U.S. before the higher tariffs take effect.TRUMP ADMINISTRATION HITS CANADA WITH 50% TARIFF OVER ALLEGED TRADE 'DISCRIMINATION'"This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them," Trump wrote.Trump said the objective of the policy is "to protect the people of the United States."The announcement marks the latest effort by the Trump administration to use tariffs as leverage to encourage domestic manufacturing in industries it considers strategically important, including pharmaceuticals. The administration has repeatedly argued that the U.S. has become overly dependent on foreign countries for critical medicines and pharmaceutical ingredients.Trump said his administration's existing policy on patented, branded and innovative drugs would remain unchanged.WHAT ARE THE MAIN STICKING POINTS IN THE TRUMP ADMIN'S TRADE NEGOTIATIONS WITH CANADA, MEXICO?"The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is," he wrote.He also pointed to what he described as a surge in domestic investment by drugmakers."Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America," Trump wrote.The Association for Accessible Medicines, which represents generic drug manufacturers, said it is seeking additional details on the proposal but supports policies that strengthen domestic manufacturing."We need to understand more the specifics of the policy, but the generics industry is committed to pursuing policies that support and stabilize both the industry and the access necessary to ensure patients have reliable… [TheTopNews] Read More.4 hours ago
- Allergy medication recalled over possible drug mix-up that could trigger ‘...Federal regulators on Monday announced the recall of a popular allergy medication over concerns that it may have been cross-contaminated with another drug, potentially causing "life-threatening" reactions.The U.S. Food and Drug Administration (FDA) said certain lots of Cetirizine Hydrochloride Tablets, commonly sold over the counter as generic versions of Zyrtec, are affected by the voluntary recall.The recall was initiated Saturday by Unique Pharmaceutical Laboratories, a division of J.B. Chemicals & Pharmaceuticals Ltd., based in Panoli, Gujarat, India, according to the FDA.The affected tablets may be contaminated with ranitidine, a medication once widely used to reduce stomach acid production. Ranitidine, sold under the brand name Zantac, was removed from the U.S. market in 2020 after regulators raised concerns over contamination with a probable human carcinogen. A reformulated version of the medication was later approved by regulators in 2025.FDA SAYS TAYLOR FARMS CYCLOSPORA LETTUCE TEST WAS A FALSE POSITIVEThe FDA warned that some consumers could experience "serious adverse events," including anaphylaxis, a rapid and potentially life-threatening allergic reaction."For consumers with a hypersensitivity to the ingredients in ranitidine, there is a reasonable probability that ingestion of Cetirizine tablets contaminated with ranitidine could result in serious adverse events," the FDA said. Anaphylaxis symptoms may manifest as low blood pressure, difficulty breathing, trouble swallowing, swelling of the throat or face, intense itching, hives and loss of consciousness. Unique Pharmaceuticals said it has not received any reports of adverse events associated with the recall.POPULAR GARLIC POWDER RECALLED NATIONWIDE OVER BACTERIAL CONTAMINATION CONCERNSThe issue was discovered after a pharmacy technician noticed discrepancies while counting tablets during dispensing, according to regulators. Some tablets appeared to have a "red dot," while others appeared discolored or had multiple red-colored spots. The recalled products were reportedly distributed nationwide to wholesalers and retailers.CLICK HERE TO GET FOX BUSINESS ON THE GOThe affected antihistamine is packaged in a high-density polyethylene (HDPE) bottle containing 100 tablets of 5 mg Cetirizine Hydrochloride Tablets USP under the National Drug Code (NDC) 16571-401-10.Four manufacturing lots are included in the recall: GY825029, GY825030, GY825031 and GY825032.All affected lots have an expiration date of October 2028. Unique Pharmaceuticals has notified its distributor, Rising Pharma Holdings Inc., of the recall. Consumers with questions about the recall can contact Rising Pharma Holdings Inc. at 1-844-874-7464 from 8 a.m. to 5 p.m. ET, Monday through Friday, or email pv@risingpharma.com. [TheTopNews] Read More.4 hours ago
The Searchable USWebDaily.com and TheTopNews NewsBank Helps You Be Better Informed, Faster! Spread The Word.
